Aiforia Digital Pathology AI, represented in New Zealand.
Translyx is authorised to represent Aiforia Clinical Suites and Aiforia Create Platform in New Zealand — helping pathology, research, preclinical, and healthcare organisations evaluate AI-assisted digital pathology workflows.
Transparent AI overlayHuman review remains central · official product imagery from Aiforia
Who this is for
Pathology Laboratories
AI-assisted scoring, grading, and quantitative outputs for clinical workflows
Research Teams
Deep learning model development for histological image analysis
Preclinical & Non-Clinical
GLP-oriented study workflows and automated image analysis
Pharma & CROs
Standardised, reproducible analysis for clinical and preclinical studies
What Translyx represents
Translyx Limited is an authorised non-exclusive business partner of Aiforia Technologies Plc in New Zealand. This authorisation covers the representation and promotion of Aiforia products and associated services under two primary brand names:
Aiforia Clinical Suites
AI-assisted clinical pathology workflows with standardised scoring and quantitative outputs
Aiforia Create Platform
Cloud-based deep learning model development for histological image analysis
Translyx helps New Zealand pathology laboratories, research teams, and healthcare organisations evaluate how Aiforia's digital pathology AI can strengthen their workflows — from clinical scoring to preclinical study management.
Authorisation details
Authorised non-exclusive business partner of Aiforia Technologies Plc
Territory: New Zealand
Authorised to represent and promote Aiforia products and associated services
Covers Aiforia Clinical Suites and Aiforia Create Platform
Authorisation valid for one year from April 2026
Non-transferable; may be withdrawn by Aiforia at any time
AI-assisted clinical pathology workflows
Aiforia Clinical Suites combine a worklist, interactive Clinical Viewer, quantitative AI models and case-level reporting for explainable first-read support.
Official Aiforia clinical imageryClinical Viewer language
Evidence that remains visible at the point of review.
Aiforia presents detailed visual overlays directly on whole-slide images, enabling pathologists to confirm findings while working with quantitative results and case-level reports.
Breast Cancer Suite
- Breast Cancer Grading
- ER
- PR
- HER2
- Ki67
- Lymph Node Metastasis
CE-IVD marked in EU/EEA
Prostate Cancer Suite
- Prostate Cancer Biopsy
- PNI
- G4 Cribriform
- HG-PIN
Select models CE-IVD marked in EU/EEA
Lung Cancer Suite
- Lung Cancer PD-L1
CE-IVD marked in EU/EEA
Gastric Suite
- Gastric Cancer
- H. pylori
Select models CE-IVD marked in EU/EEA
Colon Suite
- QuantCRC
- Lymph Node Metastasis
Select models under performance studies
Lymph Node Metastasis
- Breast cancer metastasis
- Melanoma metastasis
- Colorectal cancer metastasis
CE-IVD marked in EU/EEA for select indications
Aiforia Create Platform
Research Use Only
Aiforia Create is a cloud-based platform for developing deep learning AI models that analyse 2D images in digital pathology. It is designed for research teams, preclinical groups, and organisations that need to build and validate custom AI models for histological image analysis.
The platform provides an intuitive, no-code interface — users can train, validate, and deploy models without data science or software programming expertise.
Research & Preclinical
Aiforia Research Solutions
Aiforia also provides research solution workflows including Aiforia Studies — a software module designed for non-clinical studies that need to adhere to GLP guidelines. This supports preclinical histology study management with automated, study-centric workflows.
Applications span tissue and tumour detection, immunofluorescence analysis, lesion-specific analysis, bone marrow cell analysis, and neuron quantification.
Regulatory and intended-use note
Regulatory status and intended use vary by product and jurisdiction. Several Aiforia Clinical Suite models carry CE-IVD marking for diagnostic use in the EU/EEA. Outside the EU/EEA, these models may be classified as Research Use Only or Performance Studies Only.
Translyx supports responsible local evaluation and adoption in New Zealand. Product-specific regulatory status, intended use, and applicable local requirements should be confirmed with Aiforia Technologies Plc and relevant regulatory authorities.
Translyx does not claim or imply Medsafe approval, TGA listing, or any jurisdiction-specific regulatory endorsement for Aiforia products unless explicitly confirmed.
How Aiforia connects with the broader Translyx ecosystem
Digital pathology AI
Aiforia strengthens Translyx's oncology biomarker, precision medicine, and research portfolio with AI-assisted pathology workflows.
Pipeline capabilities
Translyx pipeline capabilities under evaluation — covering data protection, clinical documentation, and governed evidence workflows — sit alongside pathology AI.
Diagnostic pipeline
Aiforia sits alongside AMR, sepsis, POCT, cardiac, and endocrine diagnostics in Translyx's broader clinical technology portfolio.
How Translyx supports your Aiforia evaluation
Walkthrough
See the product in the context of your own workflows, with a Translyx-led session tailored to your organisation.
Clinical fit assessment
Translyx works with your team to assess relevance, workflow fit, and the questions that matter to your clinicians.
Governance & evaluation
Regulatory status, data handling, and local requirements are reviewed alongside your governance stakeholders.
Local adoption support
Translyx supports implementation, training, and ongoing regional relationship management.
Discuss Aiforia for your pathology lab or research team
Translyx can walk your team through Aiforia Clinical Suites, Aiforia Create, and research workflows — and help you evaluate how AI-assisted digital pathology fits your organisation's needs.